Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.

Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dhiraj Kumar Singh, Sultan Tousif, Ashima Bhaskar, Annu Devi, Kriti Negi, Barnani Moitra, Anand Ranganathan, Ved Prakash Dwivedi, Gobardhan Das
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/93fb6bb20ab94443ba71835315feeff6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:93fb6bb20ab94443ba71835315feeff6
record_format	dspace
spelling	oai:doaj.org-article:93fb6bb20ab94443ba71835315feeff62021-12-02T20:00:22ZLuteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.1553-73661553-737410.1371/journal.ppat.1009805https://doaj.org/article/93fb6bb20ab94443ba71835315feeff62021-08-01T00:00:00Zhttps://doi.org/10.1371/journal.ppat.1009805https://doaj.org/toc/1553-7366https://doaj.org/toc/1553-7374Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resistant Mycobacterium tuberculosis variants. Therefore, alternate host directed strategies that can shorten treatment length and enhance anti-TB immunity during the treatment phase are urgently needed. Here, we show that Luteolin, a plant-derived hepatoprotective immunomodulator, when administered along with isoniazid as potential host directed therapy promotes anti-TB immunity, reduces the length of TB treatment and prevents disease relapse. Luteolin also enhances long-term anti-TB immunity by promoting central memory T cell responses. Furthermore, we found that Luteolin enhances the activities of natural killer and natural killer T cells, both of which exhibit antitubercular attributes. Therefore, the addition of Luteolin to conventional antibiotic therapy may provide a means to avoid the development of drug-resistance and to improve disease outcome.Dhiraj Kumar SinghSultan TousifAshima BhaskarAnnu DeviKriti NegiBarnani MoitraAnand RanganathanVed Prakash DwivediGobardhan DasPublic Library of Science (PLoS)articleImmunologic diseases. AllergyRC581-607Biology (General)QH301-705.5ENPLoS Pathogens, Vol 17, Iss 8, p e1009805 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5
spellingShingle	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5 Dhiraj Kumar Singh Sultan Tousif Ashima Bhaskar Annu Devi Kriti Negi Barnani Moitra Anand Ranganathan Ved Prakash Dwivedi Gobardhan Das Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.
description	Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resistant Mycobacterium tuberculosis variants. Therefore, alternate host directed strategies that can shorten treatment length and enhance anti-TB immunity during the treatment phase are urgently needed. Here, we show that Luteolin, a plant-derived hepatoprotective immunomodulator, when administered along with isoniazid as potential host directed therapy promotes anti-TB immunity, reduces the length of TB treatment and prevents disease relapse. Luteolin also enhances long-term anti-TB immunity by promoting central memory T cell responses. Furthermore, we found that Luteolin enhances the activities of natural killer and natural killer T cells, both of which exhibit antitubercular attributes. Therefore, the addition of Luteolin to conventional antibiotic therapy may provide a means to avoid the development of drug-resistance and to improve disease outcome.
format	article
author	Dhiraj Kumar Singh Sultan Tousif Ashima Bhaskar Annu Devi Kriti Negi Barnani Moitra Anand Ranganathan Ved Prakash Dwivedi Gobardhan Das
author_facet	Dhiraj Kumar Singh Sultan Tousif Ashima Bhaskar Annu Devi Kriti Negi Barnani Moitra Anand Ranganathan Ved Prakash Dwivedi Gobardhan Das
author_sort	Dhiraj Kumar Singh
title	Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.
title_short	Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.
title_full	Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.
title_fullStr	Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.
title_full_unstemmed	Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.
title_sort	luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/93fb6bb20ab94443ba71835315feeff6
work_keys_str_mv	AT dhirajkumarsingh luteolinasapotentialhostdirectedimmunotherapyadjuncttoisoniazidtreatmentoftuberculosis AT sultantousif luteolinasapotentialhostdirectedimmunotherapyadjuncttoisoniazidtreatmentoftuberculosis AT ashimabhaskar luteolinasapotentialhostdirectedimmunotherapyadjuncttoisoniazidtreatmentoftuberculosis AT annudevi luteolinasapotentialhostdirectedimmunotherapyadjuncttoisoniazidtreatmentoftuberculosis AT kritinegi luteolinasapotentialhostdirectedimmunotherapyadjuncttoisoniazidtreatmentoftuberculosis AT barnanimoitra luteolinasapotentialhostdirectedimmunotherapyadjuncttoisoniazidtreatmentoftuberculosis AT anandranganathan luteolinasapotentialhostdirectedimmunotherapyadjuncttoisoniazidtreatmentoftuberculosis AT vedprakashdwivedi luteolinasapotentialhostdirectedimmunotherapyadjuncttoisoniazidtreatmentoftuberculosis AT gobardhandas luteolinasapotentialhostdirectedimmunotherapyadjuncttoisoniazidtreatmentoftuberculosis
_version_	1718375737911672832

Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.

Ejemplares similares